Abbott Received CE Mark for Volt™ Pulsed Field Ablation System, Offering New Therapy Option for Heart Rhythm Disorders
On March 27, 2025, Abbott announced that it received the CE Mark in Europe for its VoltTM Pulsed Field Ablation (PFA) System, designed to treat patients with atrial fibrillation (AFib). The early CE Mark approval allowed Abbott to begin commercial PFA cases across the EU with physicians who have gained experience with the system during Abbott's clinical trials. The company plans to expand the use of Volt throughout EU markets in the second half of the year.
The Volt PFA System enhances Abbott's electrophysiology (EP) portfolio by offering ...